Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16956334 | 0.92 | ALDH1A1 (0.46) | ERN1ALDH1A1TDP1LMNAMEN1 | |
| SCHEMBL9417632 | 0.90 | ERN1 (0.57) | ERN1ALDH1A1TDP1LMNAMEN1 | |
| SCHEMBL16958780 | 0.83 | ERN1 (0.40) | ERN1ALDH1A1TDP1LMNAMEN1 | |
| SCHEMBL27985682 | 0.82 | ERN1 (0.50) | ERN1ALDH1A1TDP1LMNAMEN1 | |
| SCHEMBL9422617 | 0.81 | GPR35 (0.53) | ERN1ALDH1A1TDP1MEN1KMT2A | |
| SCHEMBL16961852 | 0.79 | ALDH1A1 (0.39) | ERN1ALDH1A1TDP1LMNAMEN1 | |
| SCHEMBL31154187 | 0.79 | GPR35 (0.56) | ERN1ALDH1A1TDP1LMNAMEN1 | |
| SCHEMBL11048252 | 0.79 | MEN1 (0.40) | ERN1ALDH1A1TDP1LMNAMEN1 | |
| SCHEMBL31023003 | 0.79 | ALDH1A1 (0.39) | ERN1ALDH1A1TDP1LMNAMEN1 | |
| SCHEMBL1458014 | 0.79 | ALDH1A1 (0.55) | ERN1ALDH1A1TDP1LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100379735-C | 1,2,3,4,7, 8-hexahydro-6H- [1,4] diazepino [6,7, 1-IJ ] quinoline derivatives as antipsychotic and antiobesity agents | WYETH CORP (US) | 2008-04-09 | — | — | CN | disclosed |
| CN-1955180-A | 1,2,3,4,7,8-hexahydro-6H-[1,4]diazepino[6,7,1-IJ] quinoline derivatives as antipsychotic and antiobesity agents | WYETH CORP (US) | 2007-05-02 | — | — | CN | disclosed |
| EP-1497294-B1 | 1,2,3,4,7,8-HEXAHYDRO-6 i H /i - 1,4 DIAZEPINO 6,7 ,1- i 1J /i QUINOLINE DERIVATIVES AS ANTIPSYCHOTIC AND ANTI OBESITY AGENTS | WYETH CORP (US) | 2007-03-28 | — | — | EP | disclosed |
| EP-1497294-B1 | 1,2,3,4,7,8-HEXAHYDRO-6 i H /i - 1,4 DIAZEPINO 6,7 ,1- i 1J /i QUINOLINE DERIVATIVES AS ANTIPSYCHOTIC AND ANTI OBESITY AGENTS | WYETH CORP (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20060154920-A1 | 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij] quinoline derivatives as antipsychotic and antiobesity agents | WYETH (US) | 2006-07-13 | — | — | US | disclosed |
| US-7071185-B2 | 1,2,3,4,7,8-hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents | WYETH (US) | 2006-07-04 | — | — | US | disclosed |
| CN-1662534-A | 1,2,3,4,7, 8-hexahydro-6H- [1,4] diazepino [6,7, 1-IJ ] quinoline derivatives as antipsychotic and antiobesity agents | WYETH CORP (US) | 2005-08-31 | — | — | CN | disclosed |
| EP-1497294-A1 | 1,2,3,4,7,8-HEXAHYDRO-6 i H /i - 1,4 DIAZEPINO 6,7 ,1- i 1J /i QUINOLINE DERIVATIVES AS ANTIPSYCHOTIC AND ANTI OBESITY AGENTS | Wyeth (US) | 2005-01-19 | — | — | EP | disclosed |
| US-20040019040-A1 | 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents | WYETH | 2004-01-29 | — | — | US | disclosed |
| WO-2003091251-A1 | 1,2,3,4,7,8-HEXAHYDRO-6H-[1,4]DIAZEPINO[6,7,1-1J]QUINOLINE DERIVATIVES AS ANTIPSYCHOTIC AND ANTIOBESITY AGENTS | WYETH (US) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154920-A1 | 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij] quinoline derivatives as antipsychotic and antiobesity agents | HTR2C, HTR7, HTR1A | ERN1 3327/4885ALDH1A1 954/4885TDP1 2574/4885 |
| US-20040019040-A1 | 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents | HTR2C, HTR1A, HTR7 | ERN1 3384/4885ALDH1A1 852/4885TDP1 2377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.